LAB vs PATH
Standard Biotools Inc (LAB) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
LAB currently screens at market cap $317.1M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the LAB and PATH stock pages for the full models.
Not investment advice.